ADI-PEG 20: Clinical Trials

13 trials of ADI-PEG 20, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 recruiting, 2 withdrawn, 1 active not recruiting. 13 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 213Completed 5, Recruiting 2, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Unknown 1
Phase 14Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1
Phase 31Recruiting 1

Follow ADI-PEG 20: new trials by email Literature Review of ADI-PEG 20 trials Research Report on ADI-PEG 20

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV)
Phase 1 / Phase 2Not yet recruitingSabine Mueller, MD, PhD972027-06-012026-11-09
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
ADI-PEG 20, Cabazitaxel, Carboplatin - Prostate Cancer
Phase 1 / Phase 2RecruitingM.D. Anderson Cancer Center302024-02-292026-09-18
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
Atezolizumab, Bevacizumab, ADI-PEG 20 - Metastatic Hepatocellular Carcinoma
Phase 1 / Phase 2WithdrawnM.D. Anderson Cancer Center2023-08-082024-08-26
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
ADI-PEG 20, Gemcitabine, Docetaxel - Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
Phase 1 / Phase 2TerminatedWashington University School of Medicine312023-04-052026-07-27
Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
Nivolumab, Pegargiminase, Resection - Resectable Hepatocellular Carcinoma
Phase 2WithdrawnM.D. Anderson Cancer Center2022-04-132023-02-16
ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme
ADI-PEG 20, Temozolomide, Placebo - Glioblastoma Multiforme (GBM)
Phase 2Active not recruitingPolaris Group1002020-09-142025-08-26
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Temozolomide, Lomustine, Regorafenib - Glioblastoma
Phase 2 / Phase 3RecruitingGlobal Coalition for Adaptive Research22502019-07-302026-11-02
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
pegylated arginine deiminase, Gemcitabine, Docetaxel - Soft Tissue Sarcoma
Phase 2CompletedWashington University School of Medicine982018-05-092025-12-11
PH 2 ADI-PEG 20 Acute Myeloid Leukemia
ADI-PEG 20 - Acute Myeloid Leukemia
Phase 2CompletedPolaris Group432015-01-062020-10-01
Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
ADI-PEG 20, Transarterial chemoembolization - Unresectable Hepatocellular Carcinoma
Phase 2CompletedPolaris Group302014-10-152018-09-04
PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy
ADI-PEG 20 - Non-Hodgkin's Lymphoma
Phase 2CompletedPolaris Group182013-12-062018-09-18
A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
ADI-PEG 20 - Malignant Pleural Mesothelioma
Phase 2UnknownBarts & The London NHS Trust702011-01-012014-11-20
Testing of ADI-PEG in Hepatocellular Carcinoma
ADI-PEG 20 - Carcinoma, Hepatocellular
Phase 2CompletedFDA Office of Orphan Products Development342002-09-012015-03-25

Conditions studied

Glioblastoma (3)  ·  Carcinoma, Hepatocellular (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Glioma (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Liver Neoplasms (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Mesothelioma, Malignant (1)  ·  Prostatic Neoplasms (1)  ·  Recurrence (1)  ·  Sarcoma (1)  ·  Small Cell Lung Carcinoma (1)

Sponsors

Polaris Group (4)  ·  M.D. Anderson Cancer Center (3)  ·  Washington University School of Medicine (2)  ·  Barts & The London NHS Trust (1)  ·  FDA Office of Orphan Products Development (1)  ·  Global Coalition for Adaptive Research (1)  ·  Sabine Mueller, MD, PhD (1)

Countries

United States (9)  ·  Taiwan (4)  ·  Australia (1)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  South Korea (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Ana Aparicio, MD (1)  ·  Christine Auberle, M.D. (1)  ·  Kuo-Chen Wei, M.D. (1)  ·  Mia Weiss, M.D. (1)  ·  Pei-Jer Chen, MD, PhD (1)  ·  Peter Szlosarek (1)  ·  Sabine Mueller, MD, PhD (1)  ·  Sunyoung Lee (1)  ·  Tim Cloughesy, MD (1)  ·  Tom Davidson, MD (1)

Results publications

PMID 27584578, PMID 28900115, PMID 38773224, PMID 41980234

NIH funding

R01CA227115 (1)